Immuno-Oncology View overview page
Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?
Immune checkpoint inhibitors for AML: mechanism, rationale & using azacitidine to boost response
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
Update on checkpoint inhibitor therapy for AML: salvage, frontline & azacitidine combination
Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL
John DiPersio et al.
Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy
Alan Burnett et al.
iwAL 2018 day 1 discussion: treatment strategies in pediatric and adult ALL
Charles Mullighan et al.